This is a typical bowel control treatment pathway for a patient seeking treatment for fecal incontinence (FI).\textsuperscript{1,2} Share this pathway with your chronic FI patients, regardless of where they are on the pathway, to help them understand that there is a wide range of treatment options. Seeing the care pathway motivates patients to try another option when one fails or is unsatisfactory.

**EVALUATION**
Medical History, Physical Exam

Include information on when you should see symptom improvements and when to re-evaluate for advanced therapies.

**CONSERVATIVE THERAPIES**
- Medications
- Dietary Modifications
- Pelvic Floor Exercises
- Biofeedback

**RE-EVALUATION**

**ADVANCED THERAPIES**
- Sacral Neuromodulation delivered by the Interstim\textsuperscript{TM} system
- Dextranomer and Sodium Hyaluronate
- Anal Sphincter Repair
- Other Treatments (e.g., Artificial Sphincter, Colostomy, ACE)

Sacral Neuromodulation (SNM) is the only surgical treatment with a strong recommendation and moderate quality evidence according to the ACG Guidelines.\textsuperscript{1}
References

**InterStim® Therapy for Bowel Control** is indicated for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.

**Contraindications:** Diathermy. Patients who have not demonstrated an appropriate response to test stimulation or are unable to operate the neurostimulator.

**Warnings/Precautions/Adverse Events:**
Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 18; or for patients with progressive, systemic neurological diseases. The system may be affected by or adversely affect cardiac devices, electrocautery, defibrillators, ultrasonic equipment, radiation therapy, MRI, theft detectors/ screening devices. Adverse events include pain at the implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations, including jolting or shock sensations. Patients should be assessed preoperatively for the risk of increased bleeding. For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic’s website at www.medtronic.com. Product technical manual must be reviewed prior to use for detailed disclosure.

USA Rx Only. Rev 0815